diallyltoxiferine
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Muscarinic acetylcholine receptor M2POSITIVE ALLOSTERIC MODULATOR
CHRM2 positive allosteric modulator
Alcuronium binds to cardiac muscarinic receptors simultaneously with their specific antagonist [3H]methyl-N-scopolamine ([3H]NMS) and allosterically increases their affinity to this ligand.
Chemistry & pharmacology
Loading structure…
SMILES
C=CC[N+]12CC[C@@]34c5ccccc5N5/C=C6/[C@H]7C[C@H]8[C@@]9(CC[N@@+]8(CC=C)C/C7=C/CO)c7ccccc7N(/C=C(/[C@@H](C[C@@H]31)/C(=C\CO)C2)[C@H]54)[C@@H]69- Mol. weight
- 666.91 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1180293 ↗
- ChEMBLCHEMBL3305985 ↗
- ChEMBLCHEMBL120476 ↗
Also known as
- alcuronium
- alcuronium
- alcuronium
- alcuronium
- alcuronium
- alcuronium
- alcuronium dichloride
- allnortoxiferine
- alnortoxiferine
- dialferine
- diallylnortoxiferine
- diallyltoxiferine